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The Darwin Prospective Melioidosis Study has documented 785 melioidosis cases over 23 years. Recurrent melioidosis occurred
in 39/679 (5.7%) patients surviving initial infection; 29 patients suffered relapse of the original infection, and 10 presented with a
new Burkholderia pseudomallei infection. With improved therapy, relapse has become rare in recent years.
Burkholderia pseudomallei, the causative agent of melioidosis, isendemic to the environment of Southeast Asia and northern
Australia. Almost all B. pseudomallei infections are caused by en-
vironmental exposure to contaminated water or soils, with the
commonest route being skin inoculation or, less frequently, inha-
lation or ingestion (1). Melioidosis can present as an acute, sub-
acute, chronic, or recurrent disease and is fatal in between 10 and
50% of cases, depending on geographical region (2). Melioidosis
treatment is protracted, and recurrent disease is a well-recognized
concern, being documented for 13 to 23% of patients in Thailand
(3–7) and in 6% of patients in Australia (3, 8, 9). Recurrent me-
lioidosis can result either from relapse due to failure to clear an
infection or from reinfection with a new B. pseudomallei strain.
Since 1 October 1989, the ongoing Darwin Prospective Me-
lioidosis Study has documented all melioidosis cases in the tropi-
cal north of the Northern Territory of Australia, with the vast
majority of cases managed at Royal Darwin Hospital in the capital
city of Darwin (12.5° S). In the 23 years until 30 September 2012,
there were 785 cases of culture-confirmed melioidosis, with 106
(13.5%) dying from their initial infection. Thirty-nine (5.7%) of
the 679 survivors have subsequently presented with recurrent me-
lioidosis (Table 1). We define recurrent melioidosis as culture-
confirmed melioidosis occurring in a patient who re-presents fol-
lowing the due date for completion of their planned antibiotic
therapy (10). Therapy consists of a minimum 2 weeks of intrave-
nous antibiotics followed by a minimum 3 months of oral eradi-
cation therapy (2). Patients re-presenting during this period of
therapy are considered to have recrudescent rather than recurrent
melioidosis and have been excluded from our analysis. To classify
recurrent melioidosis cases as either relapse or reinfection, both
the initial and subsequent B. pseudomallei isolates were subjected
to multilocus sequence typing (MLST) (11). Consecutive isolates
were available for all but three cases (Table 1). This study was
approved by the Human Research Ethics Committee of the
Northern Territory Department of Health and the Menzies School
of Health Research (HREC 02/38).
Based on MLST and clinical factors, 29 (74%) of 39 recurrent
melioidosis cases were attributed to relapse. Of these 29, 26 had
identical sequence types (STs) for initial and recurrent isolates.
Paired isolates were not available for 2 of the 29 cases (identifica-
tion numbers [IDs] 121 and 238), but their time course and clin-
ical history supported relapse (Table 1). An additional patient (ID
77), previously reported by Haase and coworkers, had discordant
strains according to MLST but was thought to have relapsed from
an initial infection with multiple strains (9). Of the 29 relapse
cases, two patients relapsed twice, with one of these patients then
presenting a third time with a fatal new infection with a different
B. pseudomallei ST (i.e., reinfection after two relapses). Recurrent
melioidosis in the remaining 10 patients (26%) was attributed to
reinfection. Of these, 9 had discordant STs between initial and
recurrent isolates. Paired isolates were not available for the re-
maining patient (ID 411), but the protracted time interval (6.6
years) between infections strongly supported reinfection.
The median time from first to second admission for relapse
cases was 285 days (9.4 months), with an interquartile range of 416
days (14 months) (range, 3.3 to 28 months). For reinfection
cases, the median time between admissions was 1,643 days (54
months), with an interquartile range of 1,158 days (38 months)
(range, 10.2 to 169.4 months). We constructed a Kaplan-Meier
time-to-event curve analysis using the software program Stata
version 12 (Stata Corporation, Texas) of relapse versus reinfection
melioidosis patients, which demonstrated that reinfection cases
show increased time between disease presentations compared
with relapse patients (Fig. 1). Previous studies have reported me-
dian time spans for relapsed melioidosis of between 6 and 8
months, although it should be noted that studies conducted in
Thailand have included some patients with very early relapse
while still on therapy, which we would define as recrudescent me-
lioidosis (3, 8). Despite the difference in case definitions, the in-
creased time span for reinfection compared with relapse cases seen
in our study is consistent with findings from Thailand (3), indi-
cating that time is an important determinant of the nature of
recurrent melioidosis.
Over the past decade, we have increasingly seen a reversal of
attribution for recurrent melioidosis from predominantly re-
lapse to predominantly reinfection. Of 375 melioidosis patients
admitted prior to 30 September 2003, 24 (6.4%) have subse-
quently relapsed, in comparison to only 5 of 410 patients
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TABLE 1 Relapse and reinfection cases from the Darwin Prospective Melioidosis Study, 1 October 1989 through 30 September 2012a
Patient ID Comment Date of admissionc MSHR ID
No. of days between
admissions MLST
21 Relapse Jan. 91 73 110 135
May 91 99 135
24 Relapse Feb. 91 80 203 480
Sept. 91 118 480
52 Reinfection Apr. 92 122 426 266
June 93 223 452
77 Multiple infection—relapse Jan. 94 240 244 453
Sept. 94 335 792
81 Reinfection Feb. 94 262 1,764 678
Dec. 98 686 Not 678b
84 Relapse Feb. 94 258 618 457
Oct. 95 385 457
94 Relapse Mar. 94 281 205 109
Oct. 94 339 109
107 Relapse Dec. 94 348 139 36
May 95 377 36
109 Reinfection Jan. 95 349 343 461
Dec. 95 605 109
116 Relapse Feb. 95 364 835 429
June 97 1203 429
121 Missing paired isolate; classed as relapse due to time
frame and disease presentation
May 95 668 109 NA
Aug. 95 NA NA
126 Relapse Dec. 95 392 610 132
Aug. 97 501 132
135 Relapse Feb. 96 419 285 717
Dec. 96 459 717
136 Reinfection Mar. 96 420 5,152 36
Apr. 10 3796 327
175 Relapse Mar. 97 493 181 586
Sept. 97 524 586
179 Relapse Apr. 97 492 247 114
Dec. 97 647 114
2nd relapse Feb. 00 934 763 114
Reinfection Apr. 05 2053 1,890 Not 114b
182 Relapse Sept. 97 527 331 269
Aug. 98 1202 269
208 Relapse Mar. 98 559 657 109
2nd relapse Dec. 99 888 109
Mar. 02 1390 805 109
211 Relapse Mar. 98 628 852 327
July 00 1047 327
215 Relapse Mar. 98 663 210 36
Oct. 98 918 36
216 Relapse Mar. 98 634 309 128
Jan. 99 795 128
218 Relapse Apr. 98 641 668 729
Feb. 00 932 729
238 Missing paired isolate; classed as relapse due to time
frame and disease presentation
Dec. 98 867 237 103
Aug. 99 NA NA
259 Reinfection Feb. 99 739 2175 576
Jan. 05 1943 752
272 Relapse Mar. 99 868 140 735
Aug. 99 871 735
274 Relapse Apr. 99 848 118 434
Aug. 99 869 434
285 Relapse Dec. 99 896 101 118
Apr. 00 978 118
290 Reinfection Jan. 00 912 1,521 337
Mar. 04 1828 109
2nd reinfection Mar. 08 3029 1,470 333
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(1.2%) admitted from 1 October 2003 to 30 September 2012
(Fisher’s exact test, P  0.001). The observed decline of re-
lapsed melioidosis is most likely due to improved use of effica-
cious antimicrobials, most notably a lengthened intravenous
treatment phase for complex cases. Indeed, almost half of our
melioidosis patients now receive at least 4 weeks of intravenous
ceftazidime and/or meropenem for the primary treatment
phase, with antibiotic choice and duration based on disease
presentation and severity (2). For the last 3 years of our study
(until 30 September 2012), we have treated 252 melioidosis
patients, of which 29 cases (11.5%) were fatal. To date there has
been only one episode of relapse in these 223 survivors. These
data suggest that current antibiotic regimens are now truly
eradicating B. pseudomallei infection in patients with melioidosis.
We recognize that a limitation of our study is the assump-
tion that in all but one instance, individual infections are not
caused by multiple B. pseudomallei strains. It is also possible that
patients can be reinfected with a B. pseudomallei strain with an ST
identical to that of their primary isolate, resulting in misattribu-
tion to relapse. However, the diversity of STs observed in the
Northern Territory (12) and the increasing rarity of relapse cases
seen in our study support the notion that reinfection with an iden-
tical ST would be an infrequent occurrence. More highly resolving
molecular fingerprinting methods, such as whole-genome se-
quencing, would be required to differentiate such scenarios. Fi-
nally, we acknowledge that relapse may still occur in melioidosis
patients diagnosed toward the end of our study, although it is now
more than 16 months since the last case was admitted (June 2012).
Collectively, our data show that recurrent melioidosis in
northern Australia is in decline and is now due predominantly to
reinfection with a new strain of B. pseudomallei rather than to
relapse with the original strain. The decreased rate of relapse cases
within the Darwin Prospective Melioidosis Study over recent
years can be attributed to improved antibiotic therapy and in par-
ticular prolongation of the intravenous phase.
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Patient ID Comment Date of admissionc MSHR ID
No. of days between
admissions MLST
312 Relapse May 00 1034 202 795
Dec. 00 1068 795
316 Relapse Sept. 00 1050 245 109
May 01 1223 109
411 Missing paired isolate; classed as reinfection due to
time frame
Mar. 04 1813 2,401 749
Oct. 10 NA NA
436 Reinfection Feb. 05 1951 1,906 753
Apr. 10 3919 902
448 Relapse May 05 2077 339 109
Apr. 06 2261 109
473 Relapse Apr. 06 2255 413 798
June 07 2595 798
480 Reinfection May 06 2435 1,340 36
Jan. 10 3694 279
482 Relapse July 06 2406 458 109
Oct. 07 2861 109
544 Relapse Dec. 08 3271 686 279
Oct. 10 4383 279
613 Relapse Feb. 10 3705 492 811
June 11 5162 811
703 Reinfection Feb. 11 4694 311 466
Dec. 11 5848 553
a Abbreviations: MSHR, Menzies School of Health Research; MLST, multilocus sequence typing; NA, not applicable. Relapse melioidosis cases are shaded for clarity.
b Sequence type differed from that of original strain by at least two MLST loci.
c Month and last two digits of year.
FIG1 Kaplan-Meier time-to-event curve analysis of relapse versus reinfection
melioidosis patients within the Darwin Prospective Melioidosis Study. Thirty-
nine episodes of recurrent melioidosis occurred over the time frame of this
study; 29 episodes were due to relapse of infection, and 10 were attributed to a
new infection with B. pseudomallei. Patients presenting with reinfection are
likely to have an increased time between disease presentations compared with
that for relapse patients.
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